Eye Opening Articles & Analysis
23 news found
The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. ...
“We were impressed from the start with the acute luminal gain we were able to achieve,” says Marianne Brodmann, MD, who is a Professor and Vascular Specialist at the Medical University of Graz, Austria, and the Principal Investigator for the study. “It’s eye-opening, how the vessel responds. The device is also intuitive and easy to ...
Recent Business Highlights Generated first quarter 2022 total revenue of $14.9 million, an increase of 72% compared to the prior year period Increased the number of facilities ordering the OMNI® Surgical System from 760 in the fourth quarter of 2021 to 811 in the first quarter of 2022, and the installed base of TearCare® facilities from 562 on December 31, 2021 to 635 on March 31, ...
(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent ...
Our pioneering efforts in the development of biosimilar insulins and monoclonal antibodies have enabled us to serve several million patients in both developed and developing countries in chronic or non-communicable disease segments such as diabetes, cancer and auto-immune disorders. The COVID-19 pandemic has opened our eyes to the serious threat posed by viral ...
ByBiocon
Present in the vast majority of DED cases, MGD is largely undertreated, with no insured treatment options currently available that can address MGD as the root cause of dry eye. Meibum, a clear, oily secretion that is expressed through the eye’s meibomian glands, works to coat the outermost layer of the eye and protect tears from premature ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. ...
On World Thrombosis Day, October 13, 2021, Emosis is proud to be a "messenger" of the "Eyes open to Thrombosis" information campaign. Eyes open to Thrombosis WTD is an educational campaign to raise awareness and educate the public to the importance of reducing death and disability from thrombosis. ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation” — the highest ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever, four-year follow-up data for a MIGS device in an FDA pivotal trial. ...
” About the Hydrus® Microstent Roughly the size of an eyelash, the Hydrus® Microstent is a next-generation MIGS device designed to reduce eye pressure by reestablishing flow through Schlemm’s canal, the eye’s natural outflow pathway. ...
As a man, while I understand the struggle and recognize breast cancer has been a challenging event in a patient’s life, I’ve never walked a mile in her shoes and I don’t know many that have. This program opened my eyes and helped me better understand how important it is – what we do here at Seno ...
Karan Singh attended the conference and offered attendees an eye-opening view of the innovations that are to come to Maxcom that will cover chemicals that are not covered by GHS now, this includes, pharmaceutical drugs, Antineoplastic Drugs (Cytotoxic) and hazardous drugs, biohazardous materials and radioactive isotopes. ...
ByIncora
” Renishaw is a leading engineering company involved in a large number of outreach projects to encourage children and young people to participate in engaging STEM activities and open their eyes to STEM careers. This includes work with Greenpower, Young Engineers, Bristol Music Trust and work experience weeks awarded full recognition by the Skills for ...
The aim of the conference was to bring together the Eye on Earth partners and communities to create a widespread understanding among data providers and users about the concept of data and information sharing through the Eye on Earth Network. ...
And, because their brains, lungs, and other vital organs are still developing, children are particularly susceptible to eye, nose, and throat irritation; headaches; nausea; wheezing; coughing; dizziness; and general malaise. ...